Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib

NCT05065411 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT05065411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib
Lead sponsor
Veru Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 11, 2022
Completion date
January 9, 2024
Enrollment
5 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer